Found: 6
Select item for more details and to access through your institution.
124-LB: Development of IDG-16177, a Selective and Safe GPR40 Agonist for the Treatment of Type 2 Diabetes.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-124-LB
- By:
- Publication type:
- Article
123-LB: IDG-16177, a Potent, Orally-Bioavailable GPR40 Agonist, Improves Glycemic Control and Glucose-Stimulated Insulin Secretion in Preclinical Studies.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-123-LB
- By:
- Publication type:
- Article
122-LB: In Vitro Pharmacodynamic Studies of IDG-16177, a Potent GPR40 Agonist, for the Treatment of Type 2 Diabetes.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-122-LB
- By:
- Publication type:
- Article
118-LB: Preclinical Development of IDG-16177 as a Potent GPR40 Agonist for Treatment of Type 2 Diabetes.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-118-LB
- By:
- Publication type:
- Article
Discovery of 2,3-Dihydro-1 H-indene Derivatives as Novel GPR40 Agonists.
- Published in:
- Bulletin of the Korean Chemical Society, 2017, v. 38, n. 8, p. 861, doi. 10.1002/bkcs.11185
- By:
- Publication type:
- Article
3-Aryl-3-(isoxazol-3-yl)propanoic Acids and 2-Aryloxyacetic Acids as Potent GPR40 Agonists.
- Published in:
- Bulletin of the Korean Chemical Society, 2017, v. 38, n. 8, p. 838, doi. 10.1002/bkcs.11178
- By:
- Publication type:
- Article